1. Bjorklund A, Dunnett SB (2007) Fifty years of dopamine research. Trends Neurosci 30:185–187

2. O’Neill B, Tilley MR, Han DD, Thirtamara-Rajamani K, Hill ER, Bishop GA, Zhou FM, During MJ, Gu HH (2014) Behavior of knock-in mice with a cocaine-insensitive dopamine transporter after virogenetic restoration of cocaine sensitivity in the striatum. Neuropharmacology 79:626–633

3. Ishibashi K, Oda K, Ishiwata K, Ishii K (2014) Comparison of dopamine transporter decline in a patient with Parkinson’s disease and normal aging effect. J Neurol Sci 339:207–209

4. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, Hietala J (2001) Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 52:115–120

5. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354:2132–2133

6. German CL, Hanson GR, Fleckenstein AE (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288–297

7. Eriksen J, Jorgensen TN, Gether U (2010) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 113:27–41

8. Markota M, Sin J, Pantazopoulos H, Jonilionis R, Berretta S (2014) Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia. Schizophr Bull 40:984–991

9. Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, Rider NL, Morton DH, Strauss KA, Puffenberger EG, D’Agnano D, Anikster Y, Carducci C, Hyland K, Rotstein M, Leuzzi V, Borck G, Reith ME, Kurian MA (2014) Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 137:1107–1119

10. Lin Z, Zhang PW, Zhu X, Melgari JM, Huff R, Spieldoch RL, Uhl GR (2003) Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 278:20162–20170

11. Miranda M, Wu CC, Sorkina T, Korstjens DR, Sorkin A (2005) Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C. J Biol Chem 280:35617–35624

12. Miranda M, Dionne KR, Sorkina T, Sorkin A (2007) Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol Biol Cell 18:313–323

13. Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME (2000) Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 389:59–65

14. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78

15. Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50

16. Torres GE (2006) The dopamine transporter proteome. J Neurochem 97(Suppl 1):3–10

17. Kivell BM, Kahlig K, Galli A, Javitch JA, Shippenberg TS (2004) Regulation of dopamine transporter function and cell surface expression by kappa opioid receptors. In: 34th annual meeting of the society for neuroscience, San Diego

18. Bolan EA, Shan L, Devi LA, Javitch JA, Shippenberg TS (2004) Regulation of dopamine transporter function by kappa-opioid receptors: role of protein trafficking. In: 34th annual meeting of the society for neuroscience, San Diego

19. Pei L, Lee F, Mirecki A, Zou S, Zhang H, Vukusic B, Liu F (2004) Regulation of dopamine transporter function by dopamine D2 receptors. In: 34th annual meeting of the society for neuroscience, San Diego

20. Marazziti D, Mandillo S, Di Pietro C, Golini E, Matteoni R, Tocchini-Valentini GP (2007) GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci USA 104:9846–9851

21. Jiang H, Jiang Q, Feng J (2004) Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279:54380–54386

22. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, Liu F (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J 26:2127–2136

23. Kivell B, Uzelac Z, Sundaramurthy S, Rajamanickam J, Ewald A, Chefer V, Jaligam V, Bolan E, Simonson B, Annamalai B, Mannangatti P, Prisinzano TE, Gomes I, Devi LA, Jayanthi LD, Sitte HH, Ramamoorthy S, Shippenberg TS (2014) Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 86:228–240

24. Zisapel N, Egozi Y, Laudon M (1982) Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res 246:161–163

25. Escames G, Acuna Castroviejo D, Vives F (1996) Melatonin-dopamine interaction in the striatal projection area of sensorimotor cortex in the rat. NeuroReport 7:597–600

26. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 62:343–380

27. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP (2016) Update on melatonin receptors. IUPHAR review. Br J Pharmacol 173:2702–2725

28. Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA (2014) MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 57:3161–3185

29. Adi N, Mash DC, Ali Y, Singer C, Shehadeh L, Papapetropoulos S (2010) Melatonin MT1 and MT2 receptor expression in Parkinson’s disease. Med Sci Monit 16:BR61–67

30. Brunner P, Sozer-Topcular N, Jockers R, Ravid R, Angeloni D, Fraschini F, Eckert A, Muller-Spahn F, Savaskan E (2006) Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer’s disease. Eur J Histochem 50:311–316

31. Bendz LM, Scates AC (2010) Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother 44:185–191

32. Monteleone P, Natale M, La Rocca A, Maj M (1997) Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 36:159–163

33. Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R (2013) Minireview: toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol Endocrinol 27:1217–1233

34. Chen N, Reith ME (2008) Substrates dissociate dopamine transporter oligomers. J Neurochem 105:910–920

35. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y, Sen N, Urizar E, Gomes I, Devi LA, Ramamoorthy S, Javitch JA, Zapata A, Shippenberg TS (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71:1222–1232

36. Lam VM, Beerepoot P, Angers S, Salahpour A (2013) A novel assay for measurement of membrane-protein surface expression using a beta-lactamase. Traffic 14:778–784

37. Snider J, Kittanakom S, Damjanovic D, Curak J, Wong V, Stagljar I (2010) Detecting interactions with membrane proteins using a membrane two-hybrid assay in yeast. Nat Protoc 5:1281–1293

38. Gietz RD, Woods RA (2006) Yeast transformation by the LiAc/SS Carrier DNA/PEG method. Methods Mol Biol 313:107–120

39. Gainetdinov RR, Fumagalli F, Wang YM, Jones SR, Levey AI, Miller GW, Caron MG (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973–1978

40. Guillaume JL, Daulat AM, Maurice P, Levoye A, Migaud M, Brydon L, Malpaux B, Borg-Capra C, Jockers R (2008) The PDZ protein mupp1 promotes Gi coupling and signaling of the Mt1 melatonin receptor. J Biol Chem 283:16762–16771

41. Cecon E, Chen M, Marcola M, Fernandes PA, Jockers R, Markus RP (2015) Amyloid beta peptide directly impairs pineal gland melatonin synthesis and melatonin receptor signaling through the ERK pathway. FASEB J 29:2566–2582

42. Thomas L, Purvis CC, Drew JE, Abramovich DR, Williams LM (2002) Melatonin receptors in human fetal brain: 2-[I-125] iodomelatonin binding and MT1 gene expression. J Pineal Res 33:218–224

43. Huang X, Dai FF, Gaisano G, Giglou K, Han J, Zhang M, Kittanakom S, Wong V, Wei L, Showalter AD, Sloop KW, Stagljar I, Wheeler MB (2013) The identification of novel proteins that interact with the GLP-1 receptor and restrain its activity. Mol Endocrinol 27:1550–1563

44. Meister B, Elde R (1993) Dopamine transporter mRNA in neurons of the rat hypothalamus. Neuroendocrinology 58:388–395

45. Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M (2002) Quantitative assessment of beta 1 and beta 2-adrenergic receptor homo and hetero-dimerization by bioluminescence resonance energy transfer. J Biol Chem 277:44925–44931

46. Couturier C, Jockers R (2003) Activation of the leptin receptor by a ligand-induced conformational change of constitutive receptor dimers. J Biol Chem 278:26604–26611

47. Ayoub MA, Levoye A, Delagrange P, Jockers R (2004) Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 66:312–321

48. Couturier C, Sarkis C, Seron K, Belouzard S, Chen P, Lenain A, Corset L, Dam J, Vauthier V, Dubart A, Mallet J, Froguel P, Rouille Y, Jockers R (2007) Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity. Proc Natl Acad Sci USA 104:19476–19481

49. Brydon L, Roka F, Petit L, deCoppet P, Tissot M, Barrett P, Morgan PJ, Nanoff C, Strosberg AD, Jockers R (1999) Dual signaling of human Mel1a melatonin receptors via G(I2), G(I3), and G(Q/11) proteins. Mol Endocrinol 13:2025–2038

50. Devavry S, Legros C, Brasseur C, Delagrange P, Spadoni G, Cohen W, Malpaux B, Boutin JA, Nosjean O (2012) Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists. J Pineal Res 53:29–37

51. Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, Javitch JA, Erreger K, Galli A (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol 74:1101–1108

52. Egana LA, Cuevas RA, Baust TB, Parra LA, Leak RK, Hochendoner S, Pena K, Quiroz M, Hong WC, Dorostkar MM, Janz R, Sitte HH, Torres GE (2009) Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci 29:4592–4604

53. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383–390

54. Huff RA, Vaughan RA, Kuhar MJ, Uhl GR (1997) Phorbol esters increase dopamine transporter phosphorylation and decrease transport V max . J Neurochem 68:225–232

55. Erdozain AM, De Gois S, Bernard V, Gorgievski V, Pietrancosta N, Dumas S, Macedo CE, Vanhoutte P, Ortega JE, Meana JJ, Tzavara ET, Vialou V, Giros B (2018) Structural and functional characterization of the interaction of Snapin with the dopamine transporter: differential modulation of psychostimulant actions. Neuropsychopharmacology 43:1041–1051

56. Afonso-Oramas D, Cruz-Muros I, Alvarez de la Rosa D, Abreu P, Giraldez T, Castro-Hernandez J, Salas-Hernandez J, Lanciego JL, Rodriguez M, Gonzalez-Hernandez T (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol Dis 36:494–508

57. Sorkina T, Doolen S, Galperin E, Zahniser NR, Sorkin A (2003) Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J Biol Chem 278:28274–28283

58. Uz T, Arslan AD, Kurtuncu M, Imbesi M, Akhisaroglu M, Dwivedi Y, Pandey GN, Manev H (2005) The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system. Brain Res Mol Brain Res 136:45–53

59. Benleulmi-Chaachoua A, Chen L, Sokolina K, Wong V, Jurisica I, Emerit MB, Darmon M, Espin A, Stagljar I, Tafelmeyer P, Zamponi GW, Delagrange P, Maurice P, Jockers R (2016) Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons. J Pineal Res 60:95–108

60. Haavik J, Almas B, Flatmark T (1997) Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons? J Neurochem 68:328–332

61. Palaoglu S, Palaoglu O, Akarsu ES, Ayhan IH, Ozgen T, Erbengi A (1994) Behavioural assessment of pinealectomy and foetal pineal gland transplantation in rats: Part II. Acta Neurochir (Wien) 128:8–12

62. Poirel VJ, Masson-Pevet M, Pevet P, Gauer F (2002) MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res 946:64–71

63. Akhisaroglu M, Kurtuncu M, Manev H, Uz T (2005) Diurnal rhythms in quinpirole-induced locomotor behaviors and striatal D2/D3 receptor levels in mice. Pharmacol Biochem Behav 80:371–377

64. Ikeda E, Matsunaga N, Kakimoto K, Hamamura K, Hayashi A, Koyanagi S, Ohdo S (2013) Molecular mechanism regulating 24-hour rhythm of dopamine D3 receptor expression in mouse ventral striatum. Mol Pharmacol 83:959–967

65. Gonzalez S, Moreno-Delgado D, Moreno E, Perez-Capote K, Franco R, Mallol J, Cortes A, Casado V, Lluis C, Ortiz J, Ferre S, Canela E, McCormick PJ (2012) Circadian-related heteromerization of adrenergic and dopamine D(4) receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biol 10:e1001347

66. Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M, Robinson B, Stewart J, Amir S (2010) Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci 30:14046–14058

67. Lin CH, Huang JY, Ching CH, Chuang JI (2008) Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 44:205–213

68. Leeboonngam T, Pramong R, Sae-Ung K, Govitrapong P, Phansuwan-Pujito P (2018) Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats. J Pineal Res. https://doi.org/10.1111/jpi.12456